What drove the spike in 190A.T stock today?

The spike in 190A.T stock on 27 Feb 2026 appears driven by heavy speculative flows into small-cap oncology names and intraday momentum. No company release explained the move, so short-term trading and sector sentiment likely caused the volume surge

What are the key valuation metrics for Chordia Therapeutics (190A.T)?

Chordia (190A.T) reports EPS of -26.03, a negative PE of -4.49, price-to-book of 3.55, cash per share **JPY 33.54**, and market cap **JPY 8,211,071,700.00**, reflecting a loss-making clinical-stage biotech profile

How does Meyka AI view 190A.T stock?

Meyka AI rates 190A.T with a score out of 100: 65.53 (Grade B, Suggestion HOLD). The score blends benchmarks, sector and financial metrics. This is informational and not financial advice

What is the short-term forecast for 190A.T stock?

Meyka AI's forecast model projects a monthly price of JPY 85.73, implying a -48.69% move versus the JPY 167.00 close. Forecasts are model-based projections and not guarantees

JP Stocks

190A.T jumps 45% to JPY 167.00 on 27 Feb 2026 (JPX): assess catalyst and risk

ByHuzaifa Zahoor February 27, 2026February 27, 2026

190A.T stock led today’s most active list after Chordia Therapeutics Inc. (190A.T) surged 45.22% to JPY 167.00 on 27 Feb 2026 (JPX). Volume exploded to 45,710,300.00 shares versus an average of 972,894.00, driving a gap from the open at JPY 129.00 to a day high of JPY 167.00. The move followed increased intraday interest in the oncology sector and speculative flows into smaller biotech names. We break down why the stock was most active, the valuation backdrop, technical signals, and what Meyka AI’s model projects next